

**VIA FEDERAL EXPRESS**Food and Drug Administration  
555 Winderley Pl., Ste. 200  
Maitland, Fl 32751**WARNING LETTER**

FLA-00-37

March 6, 2000

**FACILITY ID # 217661**Robert A. Rosenweig, M.D.  
IMI of Miami  
7800 SW 87<sup>th</sup> Avenue  
Suite A-110  
Miami, Fl 33173

Dear Dr. Rosenweig:

Your facility was inspected on February 24, 2000 by a representative of the State of Florida, on contract to the Food and Drug Administration (FDA). This inspection revealed that your facility failed to comply with the Quality Standard for Mammography (Standards) as specified in Title 21, Code of Federal Regulations (CFR), Part 900.12, as follows:

**Level 1**

- The phantom image score (using an FDA approved mammography phantom) is less than three fibers.

**Level 2**

- The phantom image score (using an FDA approved mammography phantom) is less than 3 specks.
- The phantom image score (using an FDA approved mammography phantom) is less than three masses.
- There is no written procedure for infection control.

Each facility shall establish and maintain a program to assess the performance of the mammography system through the evaluation of radiographic images obtained with the phantom. The phantom images must score at least the minimum required by the accreditation body [21 CFR 900.12 (d)(2)].

Robert A. Rosenweig, M.D.

Page 2

March 6, 2000

The specific deficiencies noted above appeared on the List of Observations which was issued to your facility on February 24, 2000. These deficiencies are symptomatic of serious underlying problems that could compromise the quality of mammography at your facility.

It is your responsibility to ensure adherence to each requirement of the Mammography Quality Standards Act of 1992 (MQSA) and FDA's regulations. You are responsible for investigating and determining the cause of these deficiencies that the inspection identifies and to promptly initiate permanent corrective actions.

If you fail to properly address these deficiencies, FDA may, without further notice, initiate regulatory action. Under MQSA, FDA may:

- impose civil money penalties on a facility of up to \$10,000 for each failure to substantially comply with, or each day of failure to comply with the Standards.
- suspend or revoke a facility's FDA certificate for failure to comply with the Standards.
- seek an injunction in federal court to prohibit any mammography activity that constitutes a serious risk to human health.

Please note that FDA regulations do not preclude a State from enforcing its own State mammography laws and regulations. In some cases, these requirements may be more stringent than FDA's. When you plan your corrective action(s), therefore, you should consider the more stringent State requirements, if any.

Within 15 working days after receiving this letter, you should notify FDA in writing of each step your facility is taking to prevent the recurrence of similar violations.

If your facility is unable to complete the corrective actions within 15 working days, you should state the reason for the delay and the time within which the correction will be completed.

Robert A. Rosenweig, M.D.  
Page 2  
March 6, 2000

Your reply should be directed to Timothy J. Couzins, Compliance Officer, U.S. Food and Drug Administration, 555 Winderley Place, Suite 200, Maitland, Florida 32751, (407) 475-4728.

Sincerely,

A handwritten signature in cursive script that reads "Marie A. Urban".

Marie A. Urban  
Acting Director  
Florida District

cc: Florida Department of Health, Bureau of Radiation Control